Yang and others proposed to use avasimibe, an inhibitor of the cholesterol esterification enzyme ACAT1/SOAT1, for therapy to improve CD8+ T cell mediated control of tumor growth (Yang et al., 2016). This evidence concerns the gene CD8A and neoplasm.